Chat with us

PRIMECARE IMPEX: Trusted Brukinsa 80mg Distributor in New York

📑 Extensive Product Profile: Brukinsa 80mg Capsule

Brukinsa 80mg Capsules contain Zanubrutinib, a highly selective, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Marketed globally by BeiGene and distributed via premium oncology pathways in India by partners like Glenmark Pharmaceuticals, it represents a standard-of-care targeted therapy for progressive B-cell malignancies.

1. Clinical Indications & Usage

Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL): Indicated as first-line monotherapy or for relapsed/refractory cases, including high-risk patients displaying 17p deletion or TP53 mutations.

Mantle Cell Lymphoma (MCL): Prescribed for adult patients who have received at least one prior systemic therapy.

Waldenström’s Macroglobulinemia (WM): Utilized as a highly targeted option for adults with this rare type of non-Hodgkin lymphoma.

Marginal Zone Lymphoma (MZL): Indicated for relapsed or refractory cases where patients have received at least one anti-CD20-based regimen.

Follicular Lymphoma (FL): Deployed in combination with obinutuzumab for adults with relapsed or refractory disease after two or more lines of systemic therapy.

2. Mechanism of Action: How Brukinsa Works

Irreversible BTK Inhibition: Zanubrutinib forms a highly stable, covalent bond with a specific cysteine residue (Cys481) located in the active enzymatic pocket of Bruton's tyrosine kinase (BTK).

BCR Pathway Disruption: By locking the BTK protein into an inactive state, Brukinsa completely halts the downstream B-cell receptor (BCR) signaling cascade. It blocks essential survival routes like the PI3K-AKT and NF-κB pathways.

Suppression and Apoptosis: Deprived of these vital replication signals, malignant B-lymphocytes can no longer proliferate or spread. This forces the cancerous white blood cells to stop multiplying and undergo programmed cell death (apoptosis) while maintaining superior selectivity to limit off-target side effects.

3. Administration and Dosing Guide

Administration Route: Brukinsa is formulated as an oral 80mg hard capsule. It must be swallowed whole with water. Do not open, crush, or chew the capsules.
Food Flexibility: It can be taken safely with or without meals, at consistent times daily.

160 mg twice daily (two 80mg capsules in the morning, two 80mg capsules in the evening, approximately 12 hours apart).

320 mg once daily (four 80mg capsules taken concurrently)

⚠️ Safety, Side Effects, and Monitoring

Hemorrhage Risks: Serious and sometimes fatal bleeding events (including intracranial or GI bleeds) can happen. Care should be exercised when co-administering with blood thinners or antiplatelet agents.

Infections: Patients face increased susceptibility to severe bacterial, viral, or fungal infections (e.g., pneumonia). Prophylaxis for viral reactivations (like Hepatitis B) is recommended for at-risk cases.

Cytopenias: Significant drops in blood counts may occur. Regular Complete Blood Counts (CBC) are necessary to monitor for neutropenia, thrombocytopenia, and anemia.

Cardiac Arrhythmias: Atrial fibrillation and atrial flutter have occurred. Clinicians must monitor for fast or irregular heartbeats, chest discomfort, or sudden dizziness.

Common Side Effects: Diarrhea, muscle/joint pain, upper respiratory infections, bruising, skin rash, and high blood pressure.

📦 Storage and Handling Specifications

Climate Controls: Store between 20°C to 25°C (68°F to 77°F); excursions are provisionally allowed between 15°C to 30°C (59°F to 86°F). Store in a dry, dark warehouse setting.

Original Packaging: Keep capsules securely sealed inside their original opaque commercial bottle to protect the product from ambient moisture and direct UV degradation.

📄 Regulatory and Compliance Documentation

Authentic Certificate of Analysis (COA) from certified testing labs.
Validated Batch Origin Ledger and invoice paperwork.
GMP compliant sourcing credentials

💡 Why Choose PRIMECARE IMPEX?

Traceability
Regulatory Support
Secure Bulk Supply

📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India

[GROUP OF PRIME CARE IMPEX PVT. LTD.]

Your Trusted Pharmaceutical Exporter, Bulk Supplier, and Global Distributor from India.

🌐 Corporate Website: www.medicineexporterfromindia.com
📧 Commercial Email: exports@ernestpharmaceuticals.com
📦 Business Type: Exporter | Bulk Supplier | Distributor
📲 Direct WhatsApp Line: +91 9673008130
🔗 Instant Chat Access: https://wa.me/919673008130

📋 PRESCRIPTION MEDICINE: YES

Clinica Disclaimer: This product profile is compiled exclusively for international commercial trade research and institutional wholesale purchasing. Brukinsa 80mg Capsule is a highly restricted cytotoxic antineoplastic prescription medicine (PRESCRIPTION MEDICINE IS YES). It must be administered, managed, and dispensed solely under the supervision of a certified oncologist.

Keywords

Clomisign 50 mg Wholesale Price | Secure Pharma Export from India to US — PRIME CARE IMPEX

2026-06-04T11:21:17

Bulk Clomisign Tablets 50mg USA Distributor | Indian Exporter — PRIME CARE IMPEX

2026-06-04T11:17:21

Clomisign 50mg Cost USA | Wholesale Fertility Export from India — PRIME CARE IMPEX

2026-06-04T11:14:59

Clomiphene Citrate 50mg Supplier India to USA | Bulk Export — PRIME CARE IMPEX

2026-06-04T11:13:39

View all posts